Switch theme
Sign up to access all valuation multiples
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.
2013
69
LTM Revenue $10.4M
LTM EBITDA -$173M
$320M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Abivax has a last 12-month revenue (LTM) of $10.4M and a last 12-month EBITDA of -$173M.
In the most recent fiscal year, Abivax achieved revenue of n/a and an EBITDA of -$183M.
Abivax expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Abivax valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $10.4M | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | $10.4M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$173M | XXX | -$183M | XXX | XXX | XXX |
| EBITDA Margin | -1671% | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$192M | XXX | -$194M | XXX | XXX | XXX |
| EBIT Margin | -1859% | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$201M | XXX | -$198M | XXX | XXX | XXX |
| Net Margin | -1939% | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Abivax's stock price is EUR 5 (or $6).
Abivax has current market cap of EUR 332M (or $373M), and EV of EUR 285M (or $320M).
See Abivax trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $320M | $373M | XXX | XXX | XXX | XXX | $-3.02 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Abivax has market cap of $373M and EV of $320M.
Abivax's trades at n/a EV/Revenue multiple, and -1.8x EV/EBITDA.
Equity research analysts estimate Abivax's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Abivax has a P/E ratio of -1.9x.
See valuation multiples for Abivax and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $373M | XXX | $373M | XXX | XXX | XXX |
| EV (current) | $320M | XXX | $320M | XXX | XXX | XXX |
| EV/Revenue | 30.9x | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | -1.9x | XXX | -1.8x | XXX | XXX | XXX |
| EV/EBIT | -1.7x | XXX | -1.6x | XXX | XXX | XXX |
| EV/Gross Profit | 30.9x | XXX | n/a | XXX | XXX | XXX |
| P/E | -1.9x | XXX | -1.9x | XXX | XXX | XXX |
| EV/FCF | -1.9x | XXX | -1.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialAbivax's last 12 month revenue growth is -35%
Abivax's revenue per employee in the last FY averaged n/a, while opex per employee averaged $2.8M for the same period.
Abivax's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Abivax's rule of X is -1759% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Abivax and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -35% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | -1671% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | 16% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -1759% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $2.8M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Abivax acquired XXX companies to date.
Last acquisition by Abivax was XXXXXXXX, XXXXX XXXXX XXXXXX . Abivax acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Abivax founded? | Abivax was founded in 2013. |
| Where is Abivax headquartered? | Abivax is headquartered in France. |
| How many employees does Abivax have? | As of today, Abivax has 69 employees. |
| Who is the CEO of Abivax? | Abivax's CEO is Mr. Marc de Garidel. |
| Is Abivax publicy listed? | Yes, Abivax is a public company listed on PAR. |
| What is the stock symbol of Abivax? | Abivax trades under ABVX ticker. |
| When did Abivax go public? | Abivax went public in 2015. |
| Who are competitors of Abivax? | Similar companies to Abivax include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Abivax? | Abivax's current market cap is $373M |
| What is the current revenue of Abivax? | Abivax's last 12 months revenue is $10.4M. |
| What is the current revenue growth of Abivax? | Abivax revenue growth (NTM/LTM) is -35%. |
| What is the current EV/Revenue multiple of Abivax? | Current revenue multiple of Abivax is 30.9x. |
| Is Abivax profitable? | Yes, Abivax is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Abivax? | Abivax's last 12 months EBITDA is -$173M. |
| What is Abivax's EBITDA margin? | Abivax's last 12 months EBITDA margin is -1671%. |
| What is the current EV/EBITDA multiple of Abivax? | Current EBITDA multiple of Abivax is -1.9x. |
| What is the current FCF of Abivax? | Abivax's last 12 months FCF is -$169M. |
| What is Abivax's FCF margin? | Abivax's last 12 months FCF margin is -1629%. |
| What is the current EV/FCF multiple of Abivax? | Current FCF multiple of Abivax is -1.9x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
